Literature DB >> 15596616

Musculoskeletal pain in patients with myotonic dystrophy type 2.

Annette George1, Christiane Schneider-Gold, Sandra Zier, Karlheinz Reiners, Claudia Sommer.   

Abstract

BACKGROUND: Myotonic dystrophy type 2/proximal myotonic myopathy (DM2/PROMM) is an autosomal dominant multisystem disorder. Musculoskeletal pain is one of its frequent symptoms but also occurs in other chronic noninflammatory muscle disorders (OMD).
OBJECTIVES: To characterize the phenotype of DM2/PROMM-associated musculoskeletal pain and to test whether it shows features distinct from OMD.
SETTING: Outpatient clinic for patients with neuromuscular disorders, university hospital. PATIENTS: Twenty-four patients with DM2/PROMM (12 women and 12 men; median age, 57 years) and 24 age- and sex-matched patients with OMD consecutively recruited during a 3-year period were examined for musculoskeletal pain.
METHODS: Standardized pain assessment; McGill Pain Questionnaire; depression score; and quantification of pain thresholds to blunt pressure on limb muscles with analgometer.
RESULTS: Unlike patients with OMD who have musculoskeletal pain, patients with DM2/PROMM distinguished a wide spectrum of coexisting pain types. The major pain type in patients with DM2/PROMM was exercise-related, temperature-modulated, and palpation-induced, whereas, cramps were rare. In 8 of the patients with DM2/PROMM and in 3 of the patients with OMD, musculoskeletal pain was the most disabling symptom.
CONCLUSION: Besides many similarities, DM2/PROMM-associated musculoskeletal pain shows features distinct from OMD.

Entities:  

Mesh:

Year:  2004        PMID: 15596616     DOI: 10.1001/archneur.61.12.1938

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  19 in total

1.  [Musculoskeletal pain as the most prominent feature in myotonic dystrophy type 2].

Authors:  A George; C Schneider-Gold; K Reiners; C Sommer
Journal:  Schmerz       Date:  2006-09       Impact factor: 1.107

2.  Case 12: my doctor says that I have ALS!

Authors:  Robin K Wilson; Vinay Chaudhry
Journal:  MedGenMed       Date:  2006-03-22

3.  Diagnostic odyssey of patients with myotonic dystrophy.

Authors:  James E Hilbert; Tetsuo Ashizawa; John W Day; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  J Neurol       Date:  2013-06-27       Impact factor: 4.849

Review 4.  Sleep Complaints, Sleep and Breathing Disorders in Myotonic Dystrophy Type 2.

Authors:  Andrea Romigi; Michelangelo Maestri; Carmine Nicoletta; Giuseppe Vitrani; Marco Caccamo; Gabriele Siciliano; Enrica Bonanni; Diego Centonze; Alessandro Sanduzzi
Journal:  Curr Neurol Neurosci Rep       Date:  2019-02-09       Impact factor: 5.081

5.  Changes in pain-related beliefs, coping, and catastrophizing predict changes in pain intensity, pain interference, and psychological functioning in individuals with myotonic muscular dystrophy and facioscapulohumeral dystrophy.

Authors:  Rubén Nieto; Katherine A Raichle; Mark P Jensen; Jordi Miró
Journal:  Clin J Pain       Date:  2012-01       Impact factor: 3.442

6.  Validation of sensitivity and specificity of tetraplet-primed PCR (TP-PCR) in the molecular diagnosis of myotonic dystrophy type 2 (DM2).

Authors:  Claudio Catalli; Alessandra Morgante; Raniero Iraci; Fabrizio Rinaldi; Annalisa Botta; Giuseppe Novelli
Journal:  J Mol Diagn       Date:  2010-07-08       Impact factor: 5.568

Review 7.  Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach.

Authors:  Giovanni Meola; Fiammetta Biasini; Rea Valaperta; Elena Costa; Rosanna Cardani
Journal:  J Neurol       Date:  2017-05-26       Impact factor: 4.849

8.  Distinct neuromuscular phenotypes in myotonic dystrophy types 1 and 2 : a whole body highfield MRI study.

Authors:  Cornelia Kornblum; Götz Lutterbey; Manuela Bogdanow; Kristina Kesper; Hans Schild; Rolf Schröder; Mike Peter Wattjes
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

9.  Impact of biopsychosocial factors on chronic pain in persons with myotonic and facioscapulohumeral muscular dystrophy.

Authors:  Jordi Miró; Katherine A Raichle; Gregory T Carter; Sarah A O'Brien; Richard T Abresch; Craig M McDonald; Mark P Jensen
Journal:  Am J Hosp Palliat Care       Date:  2009-05-04       Impact factor: 2.500

10.  ClC1 chloride channel in myotonic dystrophy type 2 and ClC1 splicing in vitro.

Authors:  Simona-Felicia Ursu; Alexi Alekov; Ning-Hui Mao; Karin Jurkat-Rott
Journal:  Acta Myol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.